Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
UNLABELLED OBJECTIVE ; Weight loss improves glycemic control , lipid profiles , and blood pressure in patients with type 2 diabetes . However , successful long-term weight loss is difficult for these patients , particularly those treated with insulin . The aim of this study was to assess the effect of orlistat , a gastrointestinal lipase inhibitor , on weight loss , glycemic control , and cardiovascular risk factors in overweight or obese insulin-treated type 2 diabetic patients . RESEARCH DESIGN AND METHODS This study was a 1-year multicenter , r and omized , double-blind , placebo-controlled trial of orlistat ( 120 mg three times a day ) or placebo combined with a reduced-calorie diet in overweight or obese adults ( BMI 28 - 40 kg/m(2 ) ) with type 2 diabetes treated with insulin alone or combined with oral agents , but with suboptimal metabolic control ( HbA(1c ) 7.5 - 12.0 % ) . Outcome measurements included changes in body weight , glycemic control , blood pressure , and serum lipids . RESULTS ; After 1 year , the orlistat group lost significantly more weight ( -3.89 + /- 0.3 % of baseline body weight , means + /- SE ) than the placebo group ( -1.27 + /- 0.3 % , P < 0.001 ) . Orlistat treatment , compared with placebo , produced greater decreases in HbA(1c ) ( -0.62 + /- 0.08 vs. -0.27 + /- 0.08 % , P = 0.002 ) , fasting serum glucose ( -1.63 + /- 0.3 vs. -1.08 + /- 0.3 mmol/l , P = 0.02 ) , and the required doses of insulin and other diabetic medications . Orlistat also produced greater improvements than placebo in serum total cholesterol ( P = 0.0002 ) and LDL cholesterol concentrations ( P = 0.001 ) and LDL/HDL ratio ( P = 0.01 ) . CONCLUSIONS ; Orlistat therapy produces clinical ly significant weight loss , with improvements in glycemic control and cardiovascular disease risk factors , in overweight or obese patients with type 2 diabetes who have suboptimal metabolic control with insulin therapy
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .